Novavax, COVID
While the new mRNA vaccines from Moderna and Pfizer-BioNTech have dominated the COVID-19 vaccine story, there is another type ...
Novavax Inc. closed $10.57 below its 52-week high ($23.86), which the company reached on June 6th.
On Monday, Novavax Inc (NVAX) stock saw a decline, ending the day at $12.8 which represents a decrease of $-0.11 or -0.85% from the prior close of $12.91. The stock opened at $13.01 and touched a low ...
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...
Buying $1000 In NVAX: If an investor had bought $1000 of NVAX stock 5 years ago, it would be worth $2,000.00 today based on a ...
On Aug. 22, the U.S. Food and Drug Administration announced the approval of a new Novavax COVID vaccine, as well as updated ...
Novavax Inc. closed $11.06 below its 52-week high ($23.86), which the company achieved on June 6th.
Novavax occupies five sites in Montgomery County totaling about 370,000 square feet. Its footprint includes its headquarters ...